This looks promising I hope they do something about the long term tinnitus as well, all I hear is every one is doing research about hearing loss but not the actual tinnitus 
Audion Therapeutics Trial
- Thread starter Aaron123
- Start date
Coleoptere
Member
You might share this concern with your ENT. I still wonder how many supporting cells does a human have? And what part will be converted during treatment?
Audion's approach does reduce some of your supporting cells, but not all of them.
Member
http://www.dailymail.co.uk/health/article-5272967/Could-new-jab-men-end-hearing-aids.html
Apparently onging with 24 participants and with 10 yrs max hearing loss, as per daily mail.
Not that I am aware of.
AFAIK, Edge is no longer involved with Audion. From June 26, 2016, (Gill works for Audion)
"SYNAPSE: Does the relationship with Albert Edge's lab still continue, and how does it work in practice regarding the intellectual property coming out of his lab?
GILL: Audion has licensed technology from Mass Eye & Ear that was developed by Albert's group. Albert remains a founder of Audion, but there is no current relationship with his research group." (http://synapse.mit.edu/2016/06/26/john-gill/)
My assumption is that he has some equity in Audion but isn't involved with them any more. He's very interesting since it is his work that underlies what both Audion and Frequency are doing (and he was a senior author on McLean et al ) and is a founder at Decibel as well.
Especially this puzzles me. Audion mentions him as a consultant, and though he probably has some equity, I would expect him rather have Audion not to be successful because DX would be of more interest to him. And thus, this trial would be an EU funded research, generating data which eventually help DX to be successful. I'm curious wheter it's realistic to expect anything significant from this Audion trial.
http://www.isrctn.com/ISRCTN59733689
Still no updates, news or anything. Has there been any update about the outcome of phase 1?
Still no updates, news or anything. Has there been any update about the outcome of phase 1?
direct
Member
- Dec 3, 2014
- 20
- 63
- Tinnitus Since
- July 2014
- Cause of Tinnitus
- Loud noise at workplace in many years and the employer's negligence
A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss
REGAIN study team
Royal National Throat, Nose and Ear Hospital | 330 Grays Inn Road | London WC1X 8DA |Tel: 02031089344| Extension: 9344
ei-regain@ucl.ac.uk
http://regainyourhearing.eu
https://ukctg.nihr.ac.uk/trials/trial-details/trial-details?trialNumber=ISRCTN59733689
REGAIN study team
Royal National Throat, Nose and Ear Hospital | 330 Grays Inn Road | London WC1X 8DA |Tel: 02031089344| Extension: 9344
ei-regain@ucl.ac.uk
http://regainyourhearing.eu
https://ukctg.nihr.ac.uk/trials/trial-details/trial-details?trialNumber=ISRCTN59733689
Welcome to the REGAIN Patient Information page!
This section is designed for patients who are interested in participating in the REGAIN trial.
A drug is in development that may be able to restore hearing loss. The REGAIN study aims to test how safe the drug is and if it affects the ability to hear The REGAIN trial is currently open to participants in the UK that are able to travel to the Royal National Throat Nose and Ear Hospital in London. Compensation for your time and travel will be provided.
We hope that you find the information you are looking for here on the website. If you are interested in taking part, please contact the REGAIN team using the contact details at the bottom of this page.
Why are we doing this study?
The aim of this study is to test a new drug that may be able to treat sensorineural hearing loss. This is the most common form of hearing loss. It can be caused by damage to the hair cells lining the inner ear. When sound waves enter the inner ear, the hair cells move, which sends a signal to the nerve that runs from the ear to the brain. The brain recognises these signals as sounds.
Up until now, damage to the inner ear hair cells has been considered irreversible. Once hair cells become damaged, they will remain damaged throughout a person's life. Hearing aids can be used for people with hearing loss to amplify sounds to make it easier for damaged hair cells to detect them but there is currently no cure. Recently, scientists have made discoveries, which show that it is possible to regrow hair cells, and potentially restore hearing loss, using a drug known as a gamma secretase inhibitor.
What is the treatment?
The study drug, a gamma secretase inhibitor, is a small chemical compound that may help supporting cells in the inner ear to develop into new hair cells. It has been tested in animals in which it was found to be safe at the doses given. This is the first time the study drug LY3056480 will be tested in people. The study drug is a liquid that must be delivered to the inner ear, through the eardrum using a syringe. This technique is commonly used to deliver other drugs, such as corticosteroids, inside the ear, for example for the treatment of Meniere's Disease. Each participant will receive an injection in one ear, three times in total by an experienced Ear Nose and Throat surgeon. The same ear will be treated during the study. This will be the ear most affected by your hearing loss. If you feel there is no difference, the study doctor will decide which ear to treat.
This safety study is designed to test 4 dose levels of the study drug. A minimum of three people will receive each dose. Every participant will receive the drug. This is an open-label study, which means that both you and the research team will know which dose you are given.
Who can take part?
You may be eligible if:
For further information, please contact the REGAIN study team:
Telephone: 0203 108 9344
Email: ei-regain@ucl.ac.uk
or complete the contact form on your right.
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 634893
https://www.regainyourhearing.eu/trial/index.php
This section is designed for patients who are interested in participating in the REGAIN trial.
A drug is in development that may be able to restore hearing loss. The REGAIN study aims to test how safe the drug is and if it affects the ability to hear The REGAIN trial is currently open to participants in the UK that are able to travel to the Royal National Throat Nose and Ear Hospital in London. Compensation for your time and travel will be provided.
We hope that you find the information you are looking for here on the website. If you are interested in taking part, please contact the REGAIN team using the contact details at the bottom of this page.
Why are we doing this study?
The aim of this study is to test a new drug that may be able to treat sensorineural hearing loss. This is the most common form of hearing loss. It can be caused by damage to the hair cells lining the inner ear. When sound waves enter the inner ear, the hair cells move, which sends a signal to the nerve that runs from the ear to the brain. The brain recognises these signals as sounds.
Up until now, damage to the inner ear hair cells has been considered irreversible. Once hair cells become damaged, they will remain damaged throughout a person's life. Hearing aids can be used for people with hearing loss to amplify sounds to make it easier for damaged hair cells to detect them but there is currently no cure. Recently, scientists have made discoveries, which show that it is possible to regrow hair cells, and potentially restore hearing loss, using a drug known as a gamma secretase inhibitor.
What is the treatment?
The study drug, a gamma secretase inhibitor, is a small chemical compound that may help supporting cells in the inner ear to develop into new hair cells. It has been tested in animals in which it was found to be safe at the doses given. This is the first time the study drug LY3056480 will be tested in people. The study drug is a liquid that must be delivered to the inner ear, through the eardrum using a syringe. This technique is commonly used to deliver other drugs, such as corticosteroids, inside the ear, for example for the treatment of Meniere's Disease. Each participant will receive an injection in one ear, three times in total by an experienced Ear Nose and Throat surgeon. The same ear will be treated during the study. This will be the ear most affected by your hearing loss. If you feel there is no difference, the study doctor will decide which ear to treat.
This safety study is designed to test 4 dose levels of the study drug. A minimum of three people will receive each dose. Every participant will receive the drug. This is an open-label study, which means that both you and the research team will know which dose you are given.
Who can take part?
You may be eligible if:
- You are aged 18-80 years
- You have lived with the symptoms of hearing loss for less than 10 years
- You are using hearing aids or they have been previously offered to you
For further information, please contact the REGAIN study team:
Telephone: 0203 108 9344
Email: ei-regain@ucl.ac.uk
or complete the contact form on your right.
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 634893
https://www.regainyourhearing.eu/trial/index.php
This is great news more scientist trying to regenerate hair cells, but I honestly do want to know how the brains will respond when hair cells are regenerated, if it will reduce tinnitus if neuro plasticity is a both way ticket.
Please keep us updated!
Please keep us updated!
Someone would need to get on the trial. My hearing loss is mild, so I don't think they'd accept me and I don't need hearing aids. Someone else on here, might be able to, if they don't mention tinnitus or say it doesn't bother them as much as the hearing loss.
Simply email them or phone them and ask about the dates-
For further information, please contact the REGAIN study team:
Telephone: 0203 108 9344
Email: ei-regain@ucl.ac.uk
Hopefully they give Frequency Therapeutics a run for their money, competition is king and if more then one research lab has been able to achieve the same results then we may very well have a cure. No smoke and mirrors or investment scam but real hope.
Coming up to first anniversary for this trial. Still in phase 1, planning on starting phase 2 next year.
https://www.actiononhearingloss.org...earing-loss-to-take-part-in-a-clinical-trial/
https://www.actiononhearingloss.org...earing-loss-to-take-part-in-a-clinical-trial/
Interestingly it sounds like they would accept people with T. They are only excluding people who consider their T a bigger problem than their HL.
The worse the hearing loss, the worse the tinnitus though, right? Tinnitus is obviously more psychologically burdening so it may come across as a bigger problem. Idk
Coleoptere
Member
Good to hear from audion. Together with FX and Genvec we have 3 trials going on. It is good to have competition. That will speed things up.
Because their target is hearing loss. I dont thibk people understand how bad this condition is or else they probably would test a subgroup of shitnitus sufferers.
I don't think GenVec/Novartis trial isn't even something that will make it to market.
it's just one of those lets see what happens trials.
https://clinicaltrials.gov/ct2/show/NCT02132130
Genvec's product is going nowhere. At this point they are just trying to salvage something or continuing simply for research purposes.
Log in or register to get the full forum benefits!
Similar threads
